Clinical Trials Logo
  1. Home
  2. Sarcoidosis, Pulmonary
  3. NCT05314517

A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis — RESOLVE-Lung  

Sarcoidosis, Pulmonary Clinical Trial

Official title:
A Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary Sarcoidosis

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled study with an open-label extension (OLE).

Clinical Trial Description

This is a randomized, double-blind, placebo-controlled study with an OLE. Participants will be randomized to receive namilumab or placebo in the 26-week Double-blind Treatment Period of the study. Namilumab, or placebo, will be administered subcutaneously (SC) every 4 weeks through Week 22 after the initial dosing period. All participants, who complete the 26-week Double-blind Treatment Period, may be eligible to participate in the 28-week OLE. Further details are in the protocol. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05314517
Study type Interventional
Source Kinevant Sciences GmbH
Contact
Status Active, not recruiting
Phase Phase 2
Start date August 31, 2022
Completion date June 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT04020380 - Azithromycin a Treatment for Pulmonary Sarcoidosis Phase 2
Recruiting NCT03260556 - Pirfenidone for Progressive Fibrotic Sarcoidosis Phase 4
Completed NCT05759221 - Peripheral Airway Biopsy in Sarcoidosis N/A
Completed NCT03336736 - The Role of Physical Activity and Diet Within Pulmonary Sarcoidosis
Completed NCT03140644 - SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis N/A
Completed NCT03793439 - Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis Phase 1
Recruiting NCT04895111 - Endobronchial Ultrasound Strain Elastography in Sarcoidosis
Not yet recruiting NCT05910554 - Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis Phase 2
Recruiting NCT05374447 - Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy N/A
Active, not recruiting NCT04314193 - Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis Phase 4
Completed NCT03727451 - A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis Phase 2
Recruiting NCT05746039 - Feasibility of Semaglutide in Advanced Lung Disease Phase 1/Phase 2
Completed NCT04803617 - Investigation of Pectoralis Muscle Strength in Elderly With Interstitial Lung Disease
Recruiting NCT03145922 - Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis
Completed NCT00279708 - Atorvastatin to Treat Pulmonary Sarcoidosis Phase 2
Recruiting NCT05567133 - Risk Indicators of Sarcoidosis Evolution-Unified Protocol
Not yet recruiting NCT05291468 - the PHENOSAR Trial: Use of Antibiotics in Treatment of Sarcoidosis N/A
Completed NCT05311150 - An RCT of NBI vs. White Light Guided Endobronchial Biopsy in Suspected Sarcoidosis N/A
Completed NCT05811962 - The Diagnostic and Prognostic Role of SAA in Intrathoracic Sarcoidosis
Completed NCT03320070 - Acthar Gel in Participants With Pulmonary Sarcoidosis Phase 4